AlphaCentric Premium Opportunity Fund Class C · NASDAQ:HMXCX
AlphaCentric Premium Opportunity Fund Class C — AlphaCentric LifeSci Healthcare Fund — Investor Presentation (October 2022)
17 slides from AlphaCentric Premium Opportunity Fund Class C's investor presentation, October 2022
Slide 1: AlphaCentric LifeSci Healthcare Fund
AlphaCentric LifeSci Healthcare Fund Subadvised by LifeSci Partners, a global client services firm specializing in life sciences, medical technology and healthcare Unconstrained Biotech/Healthcare Portfolio focused on the following areas: Disruptive life sciences innovators LYFIX Robust cash f
Slide 2: A Breathtaking Number of Severe Diseases Have No Approved Therapies
A Breathtaking Number of Severe Diseases Have No Approved Therapies Context: Rare Disease Discovery Compared to FDA Approved Orphan Drugs 6,022 5,736 According to the WHO 5,484 5,230 An "orphan" disease, by US 4,980 4,764 criteria, is a rare disease that 4,498 affects fewer than 200,000 people.
Slide 3: Capital Markets Activity Fuels Biotech Innovators
Capital Markets Activity Fuels Biotech Innovators Biotech Funding Record fundraising 30,000 for the past 2 years Follow Ons helped create a record Venture Capital number of new biotech 25,000 Initial Public Offering companies. Private Investment in Public Equity The pullback that Quarterly Biote
Slide 4: Healthcare: The Investment Sector Poised for Rapid Growth
Healthcare: The Investment Sector Poised for Rapid Growth Healthcare: Secular Growth Drivers Employment in healthcare occupations is projected to grow 16% from 2020 to 2030 Expanding Access Increasing Life Expectancy That's much faster Demographic than the average for all Shift other job sectors, an
Slide 5: Mark Charest, PhD - Portfolio Manager
Mark Charest, PhD - Portfolio Manager 13+ year career as Co-founder of Fund Sub- an investor at several Advisor, LifeSci Fund specialized $1B+ AUM Management healthcare funds Co-inventor on LifeSci Fund eight biotechnology Management is an and pharmaceutical independent division patents of LifeSci P
Slide 6: Leveraging the Power of LifeSci Partners
Leveraging the Power of LifeSci Partners LifeSci Partners is a global provider of client services for key stakeholders in the life sciences, medical technology, and healthcare ecosystem, established in 2009 Financial Savvy Research-Driven Investment Banking Venture Investing Investor Communica
Slide 7: Leveraging the Power of LifeSci Partners
Leveraging the Power of LifeSci Partners LifeSci Fund Management synthesizes knowledge and insights across LifeSci Offices the global LifeSci Partners Platform to enhance fundamental due Boston diligence activities. Geneva Milan 12 Member registered research team, >500 publications annually, hosts
Slide 8: Three Thematic Investment Areas
Three Thematic Investment Areas Disruptive Robust Cash Flow/ Direct Company Funding Life Science Revenue Growth Purchase of Newly Issued Innovators Companies Primary Shares Science-driven companies Commercial stage companies with Follow-on offerings, private developing potentially exceptional
Slide 9: Investment Process
Investment Process Systematic Screening of Life Sciences Corporate Universe, INITIAL leveraging LifeSci Research Team (500+ Companies with >$1 Trillion aggregate market cap) Life Science s Corporate Universe SCREEN Triage based on scientific fundamentals and financial metrics SECTOR Perform se
Slide 10: Fund Results
Fund Results LYFIX VS. Morningstar Health (MF + ETF) Universe Manager Risk/Return December 2019 - September 2022 AlphaCentric LifeSci Healthcare I S&P Biotechnology Select Industry Index Morningstar Health (MF+ETF) Universe 20% Higher Return 15% The Fund has achieved greater returns than 10% all b
Slide 11: Fund Results
Fund Results Performance & Risk Statistics as of 9/30/22 Fund Objective Sharpe Risk-Free Cumulative Annualized Standard Ratio (RF Alpha Beta R-Squared Return Return Deviation 0.4961%) Rate The Fund’s objective is to achieve long-term capital appreciation. LYFIX 33.89% 10.83% 21.20% 0.36 3.2697% 12.4
Slide 12: Risk Disclosures
Risk Disclosures The Fund may be non-diversified and the value and/or volatility of a single issuer could have a greater impact on Fund performance. The Fund may be susceptible to an increased risk of loss due to adverse occurrences affecting the Fund more than the market as a whole, because the Fun
Slide 13: Key Definitions
Key Definitions Investment Terms Used Alpha: A measure of risk-adjusted return. Beta: A statistic that measures the volatility of the fund, as compared to that of the overall market. Risk-adjusted Alpha: A measure of the difference between a fund’s actual returns and its expected performance, given
Slide 14: Thank you for your interest in the Fund.
Thank you for your interest in the Fund. Contact Us: +1 855 674 FUND LYFIX LYFAX www.alphacentricfunds.com LYFCX info@alphacentricfunds.com
Slide 15: Appendix
Appendix LYFIX LYFAX LYFCX
Slide 16: Athira: A Direct Funding Story
Athira: A Direct Funding Story Athira Pharma (ATHA) June 2020: Fund participated in January 2021: ATHA $85M Series B Private Financing June 2021: CEO placed on leave raised $90M at 33% pending board review of her actions premium to IPO price September 2020: ATHA completes IPO stemming from doctoral
Slide 17: The LifeSci Difference
The LifeSci Difference What are the top 10 to 15 Who determines what makes the biotech stocks? Which biotech stock best and worst? should investors avoid? There are ±500 companies Fund Portfolio Manager Dr. Charest's research in this space. That's 50% Mark Charest, PhD, strives and analysis is suppo
AlphaCentric LifeSci Healthcare Fund — Investor Presentation (October 2022) on 6ix